Phenethylamine Salt Polymorphs for Stable Neuropsychiatric Dosing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for new therapeutics to treat debilitating neuropsychiatric diseases, particularly major depressive disorder and related conditions, as existing treatments are inadequate.
Innovation Solution
Development of solid forms of psychedelic compounds such as MDMA, (R)-MDMA, (S)-MDMA, MDE, S-MDE, MDAI, MBDB, S-MBDB, R-MBDB, and 5,6-Dimethoxy-2-aminoindane, including crystalline forms and salts, with improved properties like enantiomeric excess and pharmacokinetic properties, for potential therapeutic use.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing treatments are used for major depressive disorder, then current therapeutic options are available, but treatment efficacy is inadequate
Solution Approach 1:
The patent introduces novel phenethylamine compounds with modified chemical structures (different substituents, chain lengths, and configurations) to change the pharmacological parameters of existing therapies. This creates new therapeutic options with potentially improved efficacy for treatment-resistant depression while maintaining the psychoplastogenic mechanism of action.
Solution Approach 2:
The patent segments the broad class of psychoplastogenic compounds into specific phenethylamine derivatives with distinct structural features. By dividing this large class into manageable subcategories (e.g., compounds with specific R1-R6 substituents), the patent enables systematic exploration of structure-activity relationships to identify compounds with optimized therapeutic properties.
2Reliability
If solid forms of psychedelic compounds are developed, then pharmacokinetic properties are improved, but manufacturing complexity increases
Solution Approach 1:
The patent utilizes polymorphism - the ability of solid compounds to exist in multiple crystal forms - to optimize pharmacokinetic properties. By identifying and characterizing specific polymorphic forms with desirable dissolution rates, stability, and bioavailability, the patent improves drug performance without fundamentally changing the chemical structure or manufacturing approach.
Solution Approach 2:
The patent modifies physical parameters such as crystal structure, melting point, and solubility through polymorphic form selection. These parameter changes enhance pharmacokinetic properties including dissolution rate and bioavailability while using established solid-state chemistry techniques that do not significantly increase manufacturing complexity.
Data Source
AI summary
Disclosed herein are salts and solid forms of MDMA, (R)-MDMA, (S)-MDMA, MDE, S-MDE, R-MDE, MDAI, MBDB, S-MBDB, R-MBDB, MEAI, and 5,6-Dimethoxy-2-aminoindane, including salts, solid forms of the compound and salts thereof, as well as polymorphs of solid forms. The solid forms disclosed herein may have improved properties, such as improved physical, chemical, and/or pharmacokinetic properties. Also disclosed are methods for making the salts and solid forms and methods for administering the same. The disclosed salt and solid forms of MDMA, (R)-MDMA, (S)-MDMA, MDE, S-MDE, R-MDE, MDAI, MBDB, S-MBDB, R-MBDB, MEAI, and 5,6-Dimethoxy-2-aminoindane may be useful for treating neurological disease and/or a psychiatric disorder in a subject.